Doubling of Decipher Biopsy Genomic Score Is Related to Disease Reclassification on Subsequent Surveillance Biopsy but Not Adverse Features on Radical Prostatectomy. (17th March 2021)

• Record Type: Journal Article
• Authors: Ghabili, Kamyar; Paulson, Nathan; Syed, Jamil S.; Nawaf, Cayce B.; Khajir, Ghazal; Martin, Darryl T.; Onofrey, John; Leapman, Michael S.; Levi, Angelique; Weinreb, Jeffrey C.; Humphrey, Peter A.; Sprenkle, Preston C.
• Other Names: Koga Fumitaka Academic Editor.
• Is Part Of: Case reports in urology. Volume 2021(2021)
• Publication Date: 2021-03-17
• Subjects: Urology -- Periodicals; Urology -- Case studies -- Periodicals; Genitourinary organs -- Diseases -- Periodicals; Urologic Diseases; Genitourinary organs -- Diseases; Urology; Periodicals; Case studies; Periodicals; 616.6005
• DOI: 10.1155/2021/2687416
• Languages: English
• ISSNs: 2090-696X

Abstract

Abstract : The utility of serial Decipher biopsy scores in a true active surveillance population is still unknown. In a man on active surveillance for low-risk prostate cancer, a doubling of the Decipher biopsy score within genomic low-risk category from first to the second biopsy related to biopsy reclassification to Gleason grade group 4 on the third biopsy. However, the final pathology at radical prostatectomy showed Gleason grade group 2 with an organ-confined disease. This case suggests that the genomic risk category of Decipher biopsy scores during active surveillance may be more informative than either the interval genomic score change or the biopsy Gleason grade group.